Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Acute ICH
NCT03371329Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2017
- Primary completion
- Oct 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in intracerebral hemorrhage (ICH) (4 arms), sponsored by Mayo Clinic. Primary endpoint: Occurrence of adverse events at 1 year. Started Dec 2017; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT03371329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03371329.